HER-2/neu amplification determined by real-time quantitative PCR and its association with clinical outcome of breast cancer in Thailand

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 7, 2011, Pages 1703-1706

  Chariyalertsak, Sunanta ^a   Purisa, Wichai ^a   Vinyuvat, Songkhun ^b  

^a NATIONAL CANCER INSTITUTE   (Thailand)

^b Institute of Pathology   (Thailand)

Author keywords

Breast cancer; HER 2 neu gene; Real time quantitative PCR

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; REAL TIME POLYMERASE CHAIN REACTION; THAILAND; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; THAILAND; TREATMENT OUTCOME;

EID: 84864372419     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Akiyama T, Sudo C, Ogawara H, et al (1986). The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232, 1644-6.
2. Borg A, Baldetorp B, Fernö M, et al (1994). ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett, 81, 137-44.
3. Carlomagno C, Perrone F, Gallo C, et al (1996). c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol, 14, 2702-8.
4. Carr JA, Havstad S, Zarbo RJ, et al (2000). The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg, 135, 1469-74.
5. Gibson UE, Heid CA, Williams PM (1996). A novel method for real time quantitative RT-PCR. Genome Res, 6, 995-1001.
6. Gjerdrum LM, Sorensen BS, Kjeldsen E, et al (2004). Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn, 6, 42-51.
7. Gusterson BA, Gelber RD, Goldhirsch A, et al (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10, 1049-56.
8. Heid CA, Stevens J, Livak KJ, et al (1996). Real time quantitative PCR. Genome Res, 6, 986-94.
9. Kim YR, Choi JR, Song KS, et al (2002). Evaluation of HER2/neu status by real-time quantitative PCR in breast cancer. Yonsei Med J, 43, 335-40.
10. Königshoff M, Wilhelm J, Bohle RM, et al (2003). HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem, 49, 219-29.
11. Kulka J, Tôkés AM, Kaposi-Novák P, et al (2006). Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results. Pathol Oncol Res, 12, 197-204.
12. Lehmann U, Kreipe H (2001). Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods, 25, 409-18.
13. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real- time quantitation PCR and the 2 (-Delta Delta C(T)) Method. Methods, 25, 402-8.
14. Marmor MD, Skaria KB, Yarden Y (2004). Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 58, 903-13.
15. Mayr D, Heim S, Weyrauch K, et al (2009). Chromogenic in situ hybridization for HER-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology, 55, 716-23.
16. Muleris M, Almeida A, Malfoy B, et al (1997) Assignment of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) to human chromosome band 17q21.1 by in situ hybridization. Cytogenet Cell Genet, 76, 34-5.
17. Owens MA, Horten BC, Da Silva MM (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9.
18. Peiró G, Aranda FI, Adrover E, et al (2007). Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance. Hum Pathol, 38, 26-34.
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005). Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72.
20. Press MF, Bernstein L, Thomas PA, et al (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol, 15, 2894-904.
21. Quénel N, Wafflart J, Bonichon F, et al (1995). The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat, 35, 283-91.
22. Révillion F, Bonneterre J, Peyrat JP (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 34, 791-808.
23. Ring BZ, Seitz RS, Beck R, et al (2006). Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol, 24, 3039-47.
24. Riou G, Mathieu MC, Barrois M, et al (2001) c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer, 95, 266-70.
25. Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84.
26. Ross JS, Fletcher JA, Bloom KJ, et al (2004). Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3, 379-98.
27. Ross JS, Fletcher JA (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist, 3, 237-52.
28. Schechter AL, Stern DF, Vaidyanathan L, et al (1984). The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 312, 513-6.
29. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
30. Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
31. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92.
32. Smith I, Procter M, Gelber RD, et al (2007). HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36.
33. Têtu B, Brisson J, Plante V, et al (1998) p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol, 11, 823-30.
34. Tuma RS (2005). Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst, 97, 870-1.
35. van de Vijver M (2002). Emerging technologies for HER2 testing. Oncology, 63, 33-8.
36. Yarden Y (2001). Biology of HER2 and its importance in breast cancer. Oncology, 61, 1-13.
37. Yaziji H, Goldstein LC, Barry TS, et al (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-7.